This clinical trial is focused on studying a type of lung cancer known as Non-small Cell Lung Cancer (NSCLC) that can be treated with surgery. The trial aims to evaluate the safety and effectiveness of a combination of medications. These include Fianlimab and Cemiplimab, which are proteins designed to help the immune system fight cancer, and various chemotherapy drugs such as Paclitaxel, Carboplatin, Cisplatin, and Pemetrexed. Some patients will receive a combination of Fianlimab, Cemiplimab, and chemotherapy, while others will receive Cemiplimab with chemotherapy. A placebo may also be used in the study.

The purpose of the study is to determine if the combination of Fianlimab, Cemiplimab, and chemotherapy is more effective than Cemiplimab with chemotherapy alone in treating patients with resectable early-stage NSCLC. The study will involve a series of treatments administered through an intravenous (IV) infusion, which means the medication is given directly into a vein. The treatment period can last up to 54 weeks, depending on the specific combination of drugs being tested.

Throughout the study, participants will be closely monitored to assess how well the cancer responds to the treatment and to identify any side effects. The study will also look at how the treatment affects the ability to perform surgery and the overall health and quality of life of the participants. The trial is designed to provide valuable information that could improve treatment options for patients with NSCLC in the future.